2型糖尿病患者的心血管风险降低:心脏病专家需要知道什么?
Martin Berger1, Nikolaus Marx1, Katharina Marx-Schütt1
1Department of Internal Medicine I, University Hospital Aachen Aachen, Germany.
European cardiology
|May 1, 2025
概括
糖尿病患者面临更高的心血管疾病 (CVD) 风险. 本综述涵盖了目前用于降低2型糖尿病患者心血管疾病风险的治疗方法.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 糖尿病显著增加了心血管疾病 (CVD) 的风险,包括动脉样硬化CVD和心力衰竭.
- 糖尿病患者对慢性病的易感性增加,这是心血管疾病和死亡率的主要预测因素.
- 对糖尿病患者的心血管疾病和心血管疾病患者的糖尿病进行查对于及时干预至关重要.
研究的目的:
- 提供当前治疗策略的概述,以减轻2型糖尿病患者心血管风险.
主要方法:
- 本综述综合了当代关于心血管风险降低2型糖尿病治疗干预措施的证据.
主要成果:
- 该审查强调了综合查和及时治疗实施对糖尿病人群中心血管风险管理的重要性.
结论:
- 2型糖尿病的有效管理需要及时启动旨在降低心血管风险的疗法,以补充标准护理.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Carbohydrate Metabolism
10.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.5K
Diabetes: Management and Pharmacotherapy
204
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
204
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
471
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
471
Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133


